Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds CD20 on B cells. CAR engagement activates the T cells, leading to proliferation, cytokine release, and targeted cytotoxic killing (e.g., perforin/granzyme, death receptor pathways) of CD20-positive malignant and normal B cells; in some regimens paired with an anti-CD19 CAR to reduce antigen escape.